Pacific Biosciences of California develops long-read DNA sequencing systems used in research and clinical genomics. Its Single Molecule, Real-Time (SMRT) and HiFi sequencing technologies generate long, high-accuracy reads that help resolve complex regions of the genome and structural variation better than many short-read approaches. Customers include academic labs, biotech and pharmaceutical researchers, and clinical and agricultural genomics users who need detailed genomic maps and variant detection.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 39.8 | — | -41.9 | — |
| Q3 2025 | 38.4 | — | -38 | — |
| Q4 2025 | 44.6 | — | -40.4 | — |
| Q1 2026 | 37.2 | — | -8.3 | — |
| Q2 2026 | 39 | -1.9% | -44.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: LightPath Technologies, Inc. (LPTH), The Honest Company, Inc. (HNST), Elevra Lithium Limited (ELVR), Backblaze, Inc. (BLZE), Valneva SE (VALN), ProKidney Corp. (PROK)